Skip to main content
Timothy Squire Toronto Lawyer

Timothy M. Squire *

Partner | CO-LEADER, LIFE SCIENCES Fasken
Increasing government regulation continues to put more pressure on the life sciences sector in Canada.
Jurisdiction Ontario, 1997
Language(s) English
Office(s) Toronto
Contact
*practising through a professional corporation
Share
  • LinkedIn

Overview

Timothy Squire is one of Canada's leading life sciences industry practitioners. With his extensive regulatory and commercialization experience, Tim has become a trusted advisor to stakeholders in the drug, medical device, natural health product, cosmetic and food industries in Canada and from around the world.

Tim’s practice is devoted to the Life Sciences industry, and he is the Co-Leader of the firm's International Life Sciences Industry Group. He adds substantial bench strength given his extensive knowledge and experience across the entire health product lifecycle. Tim has become a trusted advisor to many stakeholders in the drug, medical device, natural health product, cosmetic and food industries in Canada and around the world due to his in-depth knowledge and commitment to client service.

Tim's regulatory practice covers all aspects of health product regulation and market access, and he is one of the few practitioners in Canada regularly called upon to help solve complex health product compliance and enforcement issues. To this end, Tim frequently communicates with Health Canada and other federal and provincial regulators on our clients’ behalf.

In addition to his regulatory acumen, Tim also negotiates and drafts sophisticated commercial arrangements for Life Sciences clients, including license agreements, distribution agreements, manufacturing and supply agreements, quality and pharmacovigilance agreements, technology and material transfer agreements, joint R&D agreements, and funding agreements.

Tim also quarterbacks regulatory due diligence in complex domestic and cross-border transactions involving drug, medical device, natural health product, cosmetic, and food companies, and is often called upon to manage post-closing integration, including the transition of market authorizations and regulatory operations.

Tim performs in-house legal functions for several U.S. and international clients without Canadian in-house legal or regulatory capabilities, and in this capacity has developed a comprehensive understanding of the business issues and pressures facing companies in the life sciences industry.

Tim’s authority in the life sciences sector has been recognized by Chambers Canada, Who’s Who Legal, Lexpert, IAM Strategy 300: The World’s Leading IP Strategists, and he has received LMG’s Life Sciences Canadian Regulatory Attorney of the Year award three times, most recently in 2020.

Achievements

  • Recognized nationwide as a Leading Partner in Life Sciences, Legal 500 2025 to 2026
  • Recognized in the Canadian Legal Lexpert Directory in Life Sciences & Health, Lexpert 2022 to 2026
  • Recognized nationwide in Life Sciences: Regulatory/Compliance, Chambers Canada 2017 to 2026
  • Recognized as Recommended in Life Sciences, Lexology Index 2021 to 2025
  • Recognized in the Canadian Legal Lexpert Directory in Biotechnology, Lexpert 2020 to 2021
  • Canadian Regulatory Attorney of the Year 2020, LMG Life Sciences Awards 2020
  • Recognized for Life Sciences, Who's Who Legal Canada 2014 to 2019
  • The World's Leading IP Strategists, IAM Strategy 300 2018
  • The World's Leading IP Strategists, IAM Strategy 300 2017
  • Recognized for Life Sciences, Who’s Who Legal 100 2014 to 2016

Experience

  • Tanabe Pharma Corporation sells global ALS Therapy business rights to Shionogi in a US$2.5 billion strategic transaction, [Deal - Tanabe Pharma Corporation], Japanese pharmaceutical company completes sale of business rights.
  • Research Capital Corporation leads bought deal public offering of Medexus Pharmaceuticals Inc., [Deal - Research Capital Corporation], Bought deal public offering of units for specialty pharmaceutical company.
  • Essa Pharma signs agreement to purchase Realm Therapeutics, [Deal - Realm Therapeutics plc], On May 16, 2019, ESSA Pharma Inc. (“ESSA”) (TSX-V: EPI; NASDAQ: EPIX) and Realm Therapeutics plc (“Realm”) (NASDAQ: RLM) announced that they entered into a definitive agreement whereby ESSA would acquire all of the issued and outstanding shares of Realm in an all-share transaction. The acquisitio...
  • Acasti Pharma completes C$27.6 million common share offering, [Deal - Mackie Research Capital Corporation], On October 23, 2018, Acasti Pharma Inc. (NASDAQ:ACST) (TSXV:ACST) (the “Company” ) closed an underwritten public offering of Class A Shares (“Common Shares”) of the Company at a price of $1.28 per Common Share for aggregate gross proceeds to the Company of $27,600,000 pursuant to an underwriting ...
  • Profound Medical completes US$17.4 million bought deal prospectus offering, [Deal - GMP Securities L.P.], On November 14, 2016, Profound Medical Corp. completed a bought deal short form prospectus offering of 15,820,000 common shares (the “Common Shares”) at an issue price of $1.10 per Common Share for aggregate gross proceeds of $17,402,000 (the “Offering”). The Offering was conducted by a syndicate...
  • Canadian nutritional product manufacturer implement protocols under the precursor regulations for the distribution of ephedrine, [Deal - Confidential Client], Timothy Squire of Fasken Martineau advised Canadian nutritional product manufacturer in the implementation of protocols under the Precursor Regulations for the distribution of ephedrine.
  • Global drug manufacturer launches formal reconsideration of Health Canada refusal to approve drug, [Deal - Confidential Client], Timothy Squire of Fasken Martineau was retained by a global drug manufacturer to challenge and help launch a formal reconsideration against Health Canada’s decision to refuse their drug approval.
  • Global smartphone manufacturer launches new mobile medical technology, [Deal - Confidential Client], Timothy Squire of Fasken Martineau advised a global smartphone manufacturer’s launch of a new mobile medical technology.
  • Global consumer product manufacturer launches new Class III medical device, [Deal - Confidential Client], Timothy Squire of Fasken Martineau was retained by a global consumer product manufacturer as they prepared for market approval and launch of new Class III medical device for laser hair removal.

Career & Education

Education

  • LLB University of Windsor
  • BA University of Windsor

Knowledge

  • Ontario Moves to Regulate Preferred Pharmacy Networks (PPNs), 11/11/2025
  • CDA Opens Public Consultation on Pharmacare National Formulary – Deadline July 18, 2025, 6/25/2025
  • Pharma and Device Compliance in Canada 2024 - 2025 Year In Review, 6/5/2025
  • Health Canada Temporarily Exempts Newly Licensed Natural Health Products from New Labelling Requirements, 4/29/2025
  • Federal Court of Appeal Rules That PMPRB Has No Jurisdiction Over Unpatented Medicine Prices: The End of the “Slender Thread” Test, 12/9/2024
  • Pharma and Device Compliance in Canada 2023 - 2024 Year In Review, 7/30/2024
  • PAAB Revisions: Real-World Evidence in Advertising, 1/15/2024
  • CADTH Publishes Guidance on Reporting Real-World Evidence, 6/29/2023
  • PAAB Publishes Draft Guidance Document on Use of Real-World Evidence in Advertising, 3/23/2023
  • Breaking News: PMPRB Opens Consultation on Draft Guidelines, 10/11/2022

Events

  • Global Antitrust Challenges Shaping the Pharmaceutical Industry, 4/16/2026
  • Drug Pricing in Canada: Navigating Potential U.S. MFN Implications, 2/6/2026
  • LSO Knowledge and Networking Breakfast: Canada’s Moment to Lead – Brain Gain & Talent Access in Canada’s Life Sciences Sector, 6/5/2025
  • LSO Knowledge and Networking Breakfast: Member Marathon Breakfast, 5/20/2025
  • LSO Knowledge and Networking Breakfast, 2/12/2025
  • Understanding Recent Regulatory Developments relating to COVID-19 Testing applicable to Ontario Healthcare Providers and Organizations, 3/31/2021
  • 'Back to School' Pharma Forum 2015, 9/24/2015
  • "Back to School" Pharma Forum, 9/18/2014
  • Medical Marihuana - Legal and Capital Markets Issues, 6/10/2014
  • Mobile Applications in Healthcare - Trends and Legal Considerations, 10/30/2013

News

  • Fasken Will Be at the BIO International Convention in San Diego, 6/8/2026
  • Fasken Will Be at the Pharma & MedTech Compliance Conference in Toronto, 5/25/2026
  • Fasken to Attend the IBA World Life Sciences Conference, 5/25/2026
  • Fasken in San Francisco for the JP Morgan Healthcare Conference Week, 1/12/2026
  • Fasken Partners with the Québec Center for Innovation in Biotechnology, 10/6/2025
  • Fasken’s Christine Elliott a Featured Guest at Life Sciences Ontario’s Ideas to Action Forum, 9/17/2025
  • Fasken Welcomes the IBA to Toronto, 5/1/2025
  • Fasken will be at the Pharma & MedTech Compliance Conference in Toronto, 4/30/2025
  • Christine Elliott of Fasken at the Canada Medtech Conference 2025, 4/25/2025
  • Fasken Wins Four LMG Life Sciences Awards, 9/23/2020

Publications

  • When is Software a Medical Device?, 5/17/2019
  • Canadian Expert Tim Squire: Bill pushing drug imports from Canada is a roundabout solution, 4/7/2017
  • U.S. Bill to Import Canadian Drugs Gets Chilly Reception North of the Border, 3/23/2017
  • Getting the Deal Through: Healthcare Enforcement & Litigation 2016 (Canada), 11/2/2015
  • Bill C-17 (Vanessa’s Law) is Almost Here - Are You Ready?, 10/22/2014
  • Life Line, 6/9/2014
  • Regulating Mobile Medical Apps in Canada, 4/1/2014
  • Life Line, 8/1/2013
  • Life Sciences, Chapter on Canada, 3/23/2012
  • Fasken Martineau's Life Sciences Newsletter, 10/27/2009
Article, Co-Author When is Software a Medical Device? Electronic Healthcare Law Review, LexisNexis, Volume 8, No. 4, May 2019, pages 44-45
Article Canadian Expert Tim Squire: Bill pushing drug imports from Canada is a roundabout solution Stat News
Article U.S. Bill to Import Canadian Drugs Gets Chilly Reception North of the Border International Trade Reporter

Speaking Engagements

  • Understand Current Interpretations and Reporting Requirements of the New Ontario Health Sector Payment Transparency Act, 2017, 6/6/2018
  • Overview of Ontario's Health Sector Payment Transparency Act, 2017 & Draft Regulations, 3/21/2018
  • The Regulation of Mobile Medical Apps as Medical Devices, 4/26/2016
  • The Medical Device Regulatory Framework in Canada, 4/18/2016
  • Minimizing Your Exposure to Liability in a New Era of Regulatory Enforcement and Transparency, 6/24/2015
  • Overview and Implementation of the Amendments to the Food and Drugs Act – Bill C-17, 6/9/2015
  • Bill C-17 and its Effect on the MedTech Industry, 4/29/2015
  • Bill C-17 Enacted by Parliament – A New Chapter in Regulatory Enforcement?, 4/8/2015
  • Crafting an Effective Internal Compliance Program, 3/31/2015
  • Government Investigations and the Pharmaceutical Company, 2/17/2015
Presenter Understand Current Interpretations and Reporting Requirements of the New Ontario Health Sector Payment Transparency Act, 2017 Pharmaceutical Compliance Congress Conference location location Toronto, ON, Canada Pharmaceutical Compliance Congress Conference
The Regulation of Mobile Medical Apps as Medical Devices 2016 MEDEC MedTech Conference location location Toronto